{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:12:40Z","timestamp":1772367160440,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.urolonc.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:52:42Z","timestamp":1589629962000},"page":"933.e7-933.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"38","author":[{"given":"Nirmish","family":"Singla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Freifeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashed A.","family":"Ghandour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon L.","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy N.","family":"Clinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas G.","family":"Petros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Robyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Chih","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur I.","family":"Sagalowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.04.025_bib0001","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eururo.2009.12.001","article-title":"Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study","volume":"57","author":"Lughezzani","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0002","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.eururo.2008.01.006","article-title":"Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors","volume":"53","author":"Zigeuner","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0004","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1016\/j.ejca.2009.06.016","article-title":"Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients","volume":"45","author":"Lughezzani","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2012.02.018","article-title":"Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery","volume":"62","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0006","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.juro.2009.02.021","article-title":"Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy","volume":"181","author":"Roscigno","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0007","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.eururo.2006.11.021","article-title":"Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival","volume":"51","author":"Lehmann","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0008","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0009","first-page":"2016","article-title":"Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Milowsky","year":"1945","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.urolonc.2016.11.018","article-title":"Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma","volume":"35","author":"Cohen","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0011","unstructured":"Almassi, N., Gao, T., Lee, B. et al.: Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery. Clin Genitourin Cancer10.1158\/1078-0432.CCR-18-2039"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0012","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00345-016-1995-z","article-title":"Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review","volume":"35","author":"Aziz","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0013","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0014","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Matin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0015","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2019.01.058","article-title":"High response rates to neoadjuvant chemotherapy in high grade upper tract urothelial carcinoma","author":"Meng","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0017","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","article-title":"Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery","volume":"16","author":"Almassi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4S","key":"10.1016\/j.urolonc.2020.04.025_bib0018","doi-asserted-by":"crossref","first-page":"e1166","DOI":"10.1016\/j.juro.2018.03.098","article-title":"LBA26 Phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma (HG UTUC): Results from ECOG-ACRIN 8141","volume":"199","author":"Hoffman-Censits","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update","volume":"73","author":"Roupret","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2011.10288.x","article-title":"Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma","volume":"109","author":"Favaretto","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0021","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urology.2009.09.048","article-title":"Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database","volume":"75","author":"Lughezzani","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.06.015","article-title":"High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy","volume":"32","author":"Raman","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0023","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","article-title":"Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy","volume":"112","author":"Xylinas","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.03.006","article-title":"Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma","volume":"33","author":"Singla","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.urology.2016.07.015","article-title":"Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma","volume":"96","author":"Singla","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0026","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","article-title":"Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy","volume":"112","author":"Xylinas","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0027","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/bju.14719","article-title":"Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma","author":"Martini","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","article-title":"Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma","volume":"200","author":"Liao","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0030","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.21551","article-title":"Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study","volume":"8","author":"Kubota","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.04.025_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040793","article-title":"Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts","volume":"20","author":"Tse","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920301800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920301800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T14:47:07Z","timestamp":1608302827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920301800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1078143920301800"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.025","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}